

To the shareholders of RELIEF THERAPEUTICS Holding SA:

Invitation to the Annual General Meeting of RELIEF THERAPEUTICS Holding SA

Thursday, 12 June 2025, 10:00 a.m. CEST

Avenue de Sécheron 15, 1202 Geneva, Switzerland

The Annual General Meeting (the "General Meeting") of shareholders of RELIEF THERAPEUTICS Holding SA (the "Company") will be held in accordance with Article 9 et seq. of the Articles of Association on Thursday, 12 June 2025, at 10:00 a.m. CEST, at Avenue de Sécheron 15, 1202 Geneva, Switzerland (doors open at 09:30 a.m.).

Agenda and Proposals of the Board of Directors

1. Approval of the 2024 Annual Report, the Annual Statutory Financial Statements, and the Annual Consolidated Financial Statements for the 2024 Financial Year

The Board of Directors proposes that the General Meeting approve the 2024 annual report, the statutory financial statements, and the consolidated financial statements for the 2024 financial year.

Explanation: Pursuant to article 698 para. 2 items 3 and 4 of the Swiss Code of Obligations ("CO"), the General Meeting is responsible for approving the annual report and the financial statements.

2. Appropriation of Available Earnings

The Board of Directors proposes to carry forward the net result for the 2024 financial year of CHF 916'291, thereby bringing the accumulated loss to CHF 257'968'557.

Explanation: Pursuant to article 698 para. 2 item 4 CO, the General Meeting is responsible for the appropriation of available earnings.

3. Discharge of the Board of Directors and the Executive Committee

The Board of Directors proposes that the General Meeting grant discharge to all current and former members of the Board of Directors and the Executive Committee for the 2024 financial year.

Explanation: Pursuant to article 698 para. 2 item 7 CO, the General Meeting is responsible for the discharge resolution.

4. Elections to the Board of Directors

4.1. Re-elections of the members of the Board of Directors

The Board of Directors proposes the individual re-election of all members of the Board of Directors for another term of office until the conclusion of the next Annual General Meeting, as follows:

- a) Re-election of Dr. Raghuram Selvaraju
- b) Re-election of Mr. Gregory Van Beek
- c) Re-election of Mr. Peter de Svastich
- d) Re-election of Mr. Thomas Elzinga

Explanation: Pursuant to article 698 para. 2 item 2 CO, the General Meeting is responsible for the elections of the members of the Board of Directors. Biographical information is available in the 2024 annual report and on the Company's website.

4.2. Re-election of the Chairman of the Board of Directors

The Board of Directors proposes the re-election of Dr. Raghuram Selvaraju as Chairman of the Board of Directors for another term of office until the conclusion of the next Annual General Meeting.

Explanation: Pursuant to article 698 para. 3 item 1 CO, the General Meeting is responsible for the above election.

4.3. Re-elections of the members of the Nomination and Compensation Committee

The Board of Directors proposes the individual re-election of the members of the Nomination and Compensation Committee for another term of office until the conclusion of the next Annual General Meeting, as follows:

- a) Re-election of Mr. Peter de Svastich
- b) Re-election of Dr. Raghuram Selvaraju

Explanation: Pursuant to article 698 para. 3 item 2 CO, the General Meeting is responsible for the above election. The elections of the members of the Nomination and Compensation Committee are held individually.

5. Compensation of the Board of Directors and the Executive Committee

5.1. Binding vote on the total compensation of the members of the Board of Directors for the period from the 2025 Annual General Meeting until the 2026 Annual General Meeting

The Board of Directors proposes the approval of a maximum total compensation of CHF 1'000'000 (fixed and variable components, including stock options and other benefits, excluding employer social security contributions) for the members of the Board of Directors for the period from this 2025 Annual General Meeting until the 2026 Annual General Meeting.

Explanation: Pursuant to article 698 para. 3 item 4 CO, the General Meeting is responsible for approving the maximum compensation of the Board of Directors. The compensation of the Board of Directors is determined based on discretionary economic considerations and may be delivered in cash and in the form of options. A description of the Company's compensation principles and amounts for the members of the Board of Directors can be found in the 2024 compensation report.

5.2. Binding vote on the total compensation of the members of the Executive Committee for the 2026 Financial Year

The Board of Directors proposes the approval of a maximum total compensation of CHF 2'000'000 (fixed and variable components, including stock options and other benefits, excluding employer social security contributions) for the members of the Executive Committee for the 2026 financial year.

Explanation: Pursuant to article 698 para. 3 item 4 CO, the General Meeting is responsible for approving the maximum compensation of the Executive Committee. The compensation of the members of the Executive Committee consists of fixed compensation, potential variable compensation, and other benefits. A description of the Company's compensation principles and amounts for the members of the Executive Committee can be found in the 2024 compensation report.

5.3. Consultative vote on the 2024 Compensation Report

The Board of Directors proposes that the General Meeting approve, on a consultative basis, the compensation report for the 2024 financial year.

Explanation: Pursuant to article 735 para. 3 item 4 CO, the Board of Directors submits the compensation report to the General Meeting for a consultative vote.

6. Re-election of the Independent Voting Rights Representative

The Board of Directors proposes the re-election of Mr. Thomas Hua, esq., partner at gbf Avocats SA, Route de Pré-Bois 20, 1215 Genève Aéroport, Switzerland, as independent proxy of the Company for another term of office until the conclusion of the next Annual General Meeting.

Explanation: Pursuant to article 698 para. 3 item 3 CO, the General Meeting is responsible for the above election. Mr. Thomas Hua fulfills the legal requirements and is available for election.

7. Re-election of the Auditors

The Board of Directors proposes the re-election of FORVIS MAZARS SA, Geneva, as the Company's statutory auditors for another term of office until the conclusion of the next Annual General Meeting.

Explanation: Pursuant to article 698 para. 2 item 2 CO, the General Meeting is responsible for the above election. FORVIS MAZARS SA fulfills the legal requirements and is available for election.

Organizational Notes

Documentation. The Company's 2024 annual report (including the statutory financial statements, the consolidated financial statements, and the compensation report) was published on 10 April 2025 and is available on the Company's website at www.relieftherapeutics.com.

Entitlement to vote. Shareholders registered in the share register as of 27 May 2025 at 05:00 p.m. CEST are entitled to vote. No registration in the share register will be made from that date through the General Meeting date. Shareholders who sell all or part of their shares prior to the General Meeting will no longer be entitled to vote to that extent.

Admission Tickets. The General Meeting will be held in person at Avenue de Sécheron 15, 1202 Geneva. Shareholders shall confirm their attendance by returning the enclosed registration form by mail, or by ordering their admission ticket through the Investor Portal, no later than 5 June 2025. Admission tickets will be sent by 9 June 2025 to shareholders who registered for the General Meeting.

Proxy Appointment. A shareholder may only be represented at the General Meeting of shareholders by their legal representative, who does not have to be a shareholder, or by means of a written or electronic proxy, or another shareholder with voting rights, or the independent proxy (by way of a written or electronic proxy). All shares held by a shareholder must be represented by a single representative. The Company shall only accept one representative per share.

Independent Proxy. The shareholders may give voting instructions to the independent proxy, Mr. Thomas Hua, esq., partner at gbf Avocats SA, route de Pré-Bois 20, 1215 Genève Aéroport, Switzerland, and exercise certain other shareholder rights through him. This may be done in writing, by mail or electronically. For the electronic instructions to the independent representative, the necessary information and login details can be found in the enclosure. Instructions transmitted electronically should be executed no later than 10 June 2025, 11.59 p.m. CEST.

Web portal "Investor Portal". The Company offers its shareholders the use of the "Investor Portal" shareholder platform to order their admission ticket, appoint a proxy and give voting instructions. Shareholders registered in the Company's share register receive the login codes with the invitation to the General Meeting. If you have questions, please contact Computershare Switzerland Ltd, operator of the online portal, by email at business.support@computershare.ch or by phone at +41 62 205 77 50 (08:00 a.m. to 05:00 p.m. CEST).

Proposals from Shareholders on Agenda Items. Proposals from shareholders on agenda items are only permissible if they are put to the General Meeting by the shareholders themselves or by an individual proxy acting on their behalf. The independent proxy cannot act as an individual proxy in this sense.

Annexes:

Registration form / Proxy with return envelope

Instruction form